Featured

Status

Health Topics

Any Category
Chemicals and Drugs
Clear Filters

Search Clinical Trials

24 Results
Active, Not Recruiting
Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I
Treatment will consist of 4 main phases: Remission Induction, Consolidation, Reinduction, and Maintenance. High risk patients will receive a reintensification phase prior to transplant in first remission. REMISSION INDUCTION: Chemotherapy …
Baylor Role: Collaborator
Recruiting
Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)
A healthy donor has given blood to make LMP/BARF1/EBNA-1 MABEL CTLs in the lab. We made the cells by first growing a special type of cells called activated T cells …
Baylor Role: Lead Sponsor
Active, Not Recruiting
iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma
Patients give blood to make GD2-T cells that are grown and frozen. To get the GD2-CAR to attach to the surface of the T-cell, a gene is inserted into the …
Baylor Role: Lead Sponsor
Recruiting
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
Patients will give the investigators blood to make CD19 CD28 (with and without CD137) chimeric receptor-T cells in the laboratory. These cells will be grown and frozen. To make the …
Baylor Role: Lead Sponsor
Completed
Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12A
At first the subject will have 2 cycles of cancer drugs (Doxorubicin, Bleomycin, Vincristine, Etoposide, Prednisone, Cyclophosphamide). The doctors call this combination of cancer drugs ABVE-PC for short. A cycle …
Baylor Role: Lead Sponsor
Active, Not Recruiting
Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita
Dyskeratosis congenita (DC) is an inherited multisystem disorder, which classically presents with a clinical triad of skin pigment abnormalities, nail dystrophy, and oral leukoplakia. DC is part of a spectrum …
Baylor Role: Collaborator
Active, Not Recruiting
Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL
The patient will give blood to make TAA-specific cytotoxic T cells in the lab. These cells will be grown and frozen. If the TAA-specific cytotoxic T cells can be made, …
Baylor Role: Lead Sponsor
Completed
Umbilical Cord Blood Transplant for Children With Myeloid Hematological Malignancies
The following will be given as the conditioning regimen for the transplant: BUSULFAN: Busulfan (intravenous BUSULFEX) dosing will be as follows: patients <12 kg: 1.1 mg/kg/dose IV every 6 hours …
Baylor Role: Lead Sponsor
Active, Not Recruiting
Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma
Because the cells have a new gene in them the patient will be followed for a total of 15 years to see if there are any long term side effects …
Baylor Role: Lead Sponsor
Terminated
T-Reg Cell Kinetics, Stem Cell Transplant, REGALE
To participate in this transplant, the patient will need to have a central line. Before the transplant we will test the blood for viruses which can cause problems after the …
Baylor Role: Lead Sponsor